MIT researchers report first broad-spectrum antiviral that, selectively, induces apoptosis in infected cells:
Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which viruses have never encountered.
More tpo come.
Hans J. Kugler, PhD
DRACO. Researchers at MIT discovered a method to kill – very specific – cells that are infected with some of the most severe viruses, like Hepatitis-C, HIV, Herpes, HPV, and more, and leaving uninfected cells untouched. All these viruses have, as an individual characteristic, double-stranded RNA (DSR). The MIT scientists built a cytotoxic T-cell by attaching 1) a receptor for double-stranded RNA, and 2) a DED (Death Effector Domain, apoptosis-inducing) part.